> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Q&A: AbbVie receives marketing authorisation from MHRA for ELAHERE
- URL: https://med-techinsights.com/abbvie-receives-marketing-authorisation-from-mhra-for-elahere/
- Published: 2025-08-08T15:00:00.000Z
- Updated: 2026-10-22T07:48:40.000Z
- Description: After AbbVie announced the marketing authorisation from MHRA for ELAHERE, Med-Tech Insights spoke to the company to find out more. When do you anticipate mirvetuximab soravtansine will be available to eligible patients? Mirvetuximab soravtansine is now licensed as a monotherapy in the UK for the tre
- Author: Olivia Friett
- Tags: Insights, Femtech, Policy & Regulation

**After** [**AbbVie announced the marketing authorisation from MHRA for ELAHERE**](https://med-techinsights.com/2025/07/25/abbvie-receives-marketing-authorisation-from-mhra/)**, Med-Tech Insights spoke to the company to find out more.**

**When do you anticipate mirvetuximab soravtansine will be available to eligible patients?**

Mirvetuximab soravtansine is now licensed as a monotherapy in the UK for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens but it is important to clarify that it is not reimbursed yet for use on the NHS in England or Scotland until the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC), respectively, have conducted their appraisals on the medicine.

We are currently going through the submission process with both NICE and the SMC. Our priority is to ensure that the evidence we provide is robust and fully addresses the requirements of both appraisal bodies. 

We are working to complete this process as thoroughly and efficiently as possible. We recognise that the speed of access to mirvetuximab soravtansine is vital for eligible women with PROC in the UK. While we cannot provide a precise submission date at this time, we are actively prioritising this work

**Are there plans for early access schemes while awaiting NICE appraisal?**

AbbVie is committed to ensuring our innovative cancer therapies, such as mirvetuximab soravtansine, are available to all eligible patients who need them. Our policy on pre-approval access is designed to protect the fair, equitable, and uninterrupted access of unapproved medications while also protecting the integrity of ongoing clinical trials. There is a global patient access scheme in place for mirvetuximab soravtansine and individual patients must speak with their clinicians for further guidance.

**How does mirvetuximab soravtansine improve patients’ quality of life compared with standard chemotherapy, beyond survival outcomes?**

The approval of mirvetuximab soravtansine by the MHRA provides a new treatment option for eligible people living with this type of ovarian cancer in the UK.

Most women with ovarian cancer are newly diagnosed with late-stage disease and typically receive surgery and platinum-based chemotherapy. Sadly, 80% of women with advanced disease relapse and the majority eventually develop resistance to this treatment, resulting in poor prognosis.

Ovarian cancer is one of the leading causes of death from gynaecological cancer in the UK. Historically, treatment options for patients with PROC have been limited, and those available often result in adverse events which can negatively impact quality of life.

**Can mirvetuximab soravtansine be used in combination with other therapies in future, or are there trials underway to explore this?**

The ongoing development programme includes evaluating mirvetuximab soravtansine in ovarian cancer as monotherapy, and in combination, in the second line plus platinum-sensitive and first-line maintenance settings, as well as for FRα medium expressors.